GALC

Across TCGA pan-cancer cohorts, GALC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALC data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GALC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALC expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where GALC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.441	0.878	<.001	25	view →
PDAC	OS	Median	All	0.272	0.478	<.001	24	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	16	view →
LUAD	DFS	Tertile	All	0.413	0.775	.004	12	view →
UCEC	OS	Quartile	III,IV	0.438	1.000	.040	4	view →
LSCC	DFS	Quartile	All	0.939	1.000	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALC–HNSC (DFS)

Open the HNSC breakdown →